Katsuhiko Naoki
Kanagawa, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 127 publications
Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 05, 2026
Epigenomic profiling of neuroendocrine lung cancers identifies a classical-neuroendocrine ASCL1/NKX2-1 subtype and a SOX11-associated differentiation axis linked to reduced immunogenicity.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 06, 2026
Disease Kinetics and Practice Patterns in ≥4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 14, 2026
MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib-Resistant MET-Amplified, EGFR-Mutated Non-Small Cell Lung Cancer.
Journal: Thoracic cancer
Published: January 18, 2026
Osimertinib opens the door for patients with EGFR-mutated advanced non-small cell lung cancer and a poor performance status: comment on the OPEN/TORG2040 trial.
Journal: Translational lung cancer research
Published: January 08, 2026
PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC.
Journal: Journal for immunotherapy of cancer
Published: November 17, 2025
Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 31, 2025
Differential predictive value of baseline tumor size according to PD-L1 expression in advanced NSCLC treated with immune checkpoint inhibitors.
Journal: Cancer treatment and research communications
Published: September 18, 2025
Cemiplimab in Japanese patients with advanced non-small cell lung cancer.
Journal: Japanese journal of clinical oncology
Published: July 11, 2025
Pleomorphic Carcinoma With EGFR and Concomitant Mutations Transformed From Lung Adenocarcinoma: A Case Report.
Journal: Cancer reports (Hoboken, N.J.)
Published: June 29, 2025
Insight Into the Significance of CD8+ Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma.
Journal: Thoracic cancer
Published: April 16, 2025
Last Updated: 09/26/2026